You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
我國首次人體內探索基因編輯造血幹細胞移植取得重要進展
格隆匯 09-18 18:48
解放軍總醫院透露,第五醫學中心造血幹細胞移植科與北京大學、北京佑安醫院合作,在艾滋病合併白血病患者的基因編輯成體造血幹細胞移植研究上取得重要進展:建立了基於CRISPR在人成體造血幹細胞上進行CCR5基因編輯的技術體系,實現了經基因編輯後的成體造血幹細胞在人體內長期穩定的造血系統重建,為後續基因編輯治療的安全性和有效性研究奠定了基礎。該研究將會推動全球範圍內基於CRISPR基因編輯手段用於臨牀治療,相關研究成果發表在《新英格蘭醫學雜誌》。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account